PSMD4 amplification

News alerts, weekly reports and conference planners

Entrez ID:

5710

Related biomarkers:

Expression

Mutation

‹

›

almost3years

IDENTIFICATION OF NOVEL TARGET GENES CORRELATED WITH 1Q21 AMPLIFICATION IN PATIENTS WITH SMOLDERING MYELOMA AND MULTIPLE MYELOMA (EHA 2023)

Subsequently, we assessed the role of PSMB4 and PSMD4 to the sensibility of PI bortezomib in two myeloma cell lines carrying 1q21+...Our study identified proteasome subunits PSMB4 and PSMD4 to be significantly upregulated in SMM and MM patients with 1q21, correlated with 1q21 copy number but not with disease stage. In addition, knockdown of both, PSMB4 and PSMD4 decreased MM cell proliferation. Therefore, targeting PSMD4 could be a strategy to treat patients with 1q21 amplification.

almost 3 years ago

Clinical

SDC1 (Syndecan 1) • PSMD4 (Proteasome 26S Subunit Non-ATPase 4)

PSMD4 amplification

bortezomib

almost5years

Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. (PubMed, J Pers Med)

The low-risk groups of both LUAD and LUSC tend to have a higher number of SNVs, CNVs, and DEGs. The signature genes and altered genes have the potential to be used as diagnostic and prognostic biomarkers for personalized oncology.

almost 5 years ago

Journal

KRAS (KRAS proto-oncogene GTPase) • PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • RBM10 (RNA Binding Motif Protein 10) • KDM5C (Lysine Demethylase 5C) • SOX2 • PSMD4 (Proteasome 26S Subunit Non-ATPase 4)

KRAS mutation • EGFR mutation • CDKN2A deletion • HRAS mutation • PAK4 deletion • EGFR mutation + KRAS mutation • PSMD4 amplification